Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > ABRAXANE Approved for Advanced Breast Cancer Patient Treatment in Quebec

Abstract:
Offers New Treatment Option for Metastatic Breast Cancer Patients

ABRAXANE Approved for Advanced Breast Cancer Patient Treatment in Quebec

Los Angeles, CA & Toronto, Canada | Posted on June 29th, 2009

Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated biotechnology company, today announced the listing of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg in Quebec for the treatment of metastatic breast cancer with a recommendation from the Quebec Conseil du Médicament and approval from the Quebec Ministry of Health. ABRAXANE is approved and commercially available in Canada for the treatment of metastatic breast cancer, including first-line disease. The listing of ABRAXANE in Quebec offers an important new treatment option to Quebec women with advanced breast cancer.

"Based on clinical study results to date and my first-hand experience, I believe that ABRAXANE represents a very important and needed new treatment option for breast cancer," said Dr. André Robidoux, Director of the Breast Cancer Research Group of the CHUM Research Center. "ABRAXANE is the only taxane that is solvent free and is approved to treat metastatic breast cancer."

The Conseil's approval was based upon comparative clinical trials demonstrating the tumor response rate of ABRAXANE was nearly double for patients who received ABRAXANE compared to those who received solvent-based paclitaxel. Patients treated with ABRAXANE experienced a significant improvement in progression-free survival and prolonged time to tumor progression compared to patients treated with solvent-based paclitaxel.i Additionally, a recently published Phase II study demonstrated that ABRAXANE (administered weekly at 150 mg/m2) nearly doubled progression-free survival over docetaxel injection (14.6 months versus 7.8 months respectively p=0.012).ii ABRAXANE is indicated in Canada at a dose of 260 mg/m2 every three weeks for the treatment of metastatic breast cancer.

ABRAXANE uses the natural properties of a human protein, albumin, to deliver the drug more effectively to tumors. By wrapping the albumin around the active drug, ABRAXANE can be administered to patients at higher doses without the use of toxic solvents - often the cause of significant treatment-related side effects with other taxane chemotherapies. Unlike most taxane chemotherapies, ABRAXANE eliminates the patient's need for premedication during treatment to avoid allergic reactions caused by solvents . Additionally, patients can receive treatment in as little at 30 minutes compared to more than three hours needed for solvent-based paclitaxel.

"With this approval, Quebec doctors and patients now have another effective treatment option to help women in their fight against advanced breast cancer," said Lyndal Walker, Vice President and Managing Director, Abraxis BioScience Canada.

According to Canadian Cancer Society statistics, an estimated 5,900 Quebec women were diagnosed with breast cancer in 2008.iii With an average of 437 women diagnosed with breast cancer every week, breast cancer is the second leading cause of cancer mortality among Canadian women.iv

ABRAXANE has now been approved in 36 countries across Europe, North America, Asia and Australia. Abraxis is continuing to expand its clinical experience with ABRAXANE and its potential in treating a variety of tumor types at multiple stages of disease as a single agent and in combination.


i Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin Oncol. 2005;23(31):7794-803.

ii Gradishar et al. Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer. J Clin Oncol. 2009; 0: JCO.2008.18.5397v1.

iii Canadian Cancer Society. Breast cancer: the facts. October 2008.
Available at: www.cancer.ca/quebec/about%20us/media%20centre/~/media/CCS/Quebec/Qui_sommes_nous/Salle_des_nouvelles/Feuilles_de_faits/Cancer_du_sein_Faits2008_QC-ang.ashx

iv Canadian Cancer Society. Breast Cancer Stats. 16 April 2009. Available at www.cancer.ca/canada-wide/about%20cancer/cancer%20statistics/stats%20at%20a%20glance/breast%20cancer.aspx?sc_lang=.

####

About Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 36 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.

About ABRAXANE®

ABRAXANE is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience's proprietary nab® technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin, a naturally-occurring human protein. By wrapping the albumin around the active drug, ABRAXANE can be administered to patients at higher doses, delivering higher concentrations of paclitaxel to the tumor site than solvent-based paclitaxel. ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: expanded applications for metastatic breast, non-small cell lung, malignant melanoma, pancreatic, gastric and head and neck.

In June 2006 ABRAXANE was approved by Therapeutic Products Directorate of Health Canada under a Notice of Compliance for the treatment of metastatic breast cancer in Canada. The U.S. Food and Drug Administration approved ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated

For more information, please click here

Contacts:
Abraxis BioScience, Inc.
Maili Bergman
310-883-1300

or
Investors and Media Inquiries
High Road Communications
Carrie Baker
416-644-2264

Copyright © Abraxis BioScience, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanotech could rid cattle of ticks, with less collateral damage September 1st, 2015

Scientists 'squeeze' light one particle at a time: A team of scientists have measured a bizarre effect in quantum physics, in which individual particles of light are said to have been 'squeezed' -- an achievement which at least one textbook had written off as hopeless September 1st, 2015

Using ultrathin sheets to discover new class of wrapped shapes: UMass Amherst materials researchers describe a new regime of wrapped shapes August 31st, 2015

New material science research may advance tech tools August 31st, 2015

Nanomedicine

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Iranian Scientists Use Artemisia Annua Plant to Produce Breast Cancer Drugs August 29th, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

Announcements

Nanotech could rid cattle of ticks, with less collateral damage September 1st, 2015

Scientists 'squeeze' light one particle at a time: A team of scientists have measured a bizarre effect in quantum physics, in which individual particles of light are said to have been 'squeezed' -- an achievement which at least one textbook had written off as hopeless September 1st, 2015

An engineered surface unsticks sticky water droplets August 31st, 2015

New material science research may advance tech tools August 31st, 2015

Nanobiotechnology

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

Nanotechnology that will impact the Security & Defense sectors to be discussed at NanoSD2015 conference August 25th, 2015

Louisiana Tech University researchers discover synthesis of a new nanomaterial: Interdisciplinary team creates biocomposite for first time using physiological conditions August 24th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic